First Human Receives Experimental Therapy to Reverse Cellular Aging
Via Gizmodo
Summary
Life Biosciences, the biotech startup cofounded by Harvard geneticist David Sinclair, has dosed its first patient in an FDA-approved clinical trial using partial cellular reprogramming to reverse aging in the eye.
The experimental drug ER-100 uses three genetic factors to reset age-related epigenetic markers in retinal neurons, targeting glaucoma patients facing irreversible vision loss — the first time a reprogramming technology has ever been tested in humans.
If successful, the trial could open a new frontier in anti-aging medicine, with implications far beyond ophthalmology.
